You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

LENACAPAVIR SODIUM - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for lenacapavir sodium and what is the scope of freedom to operate?

Lenacapavir sodium is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in two NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lenacapavir sodium has one hundred and eighty-eight patent family members in forty-six countries.

One supplier is listed for this compound.

Summary for LENACAPAVIR SODIUM
International Patents:188
US Patents:5
Tradenames:1
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
What excipients (inactive ingredients) are in LENACAPAVIR SODIUM?LENACAPAVIR SODIUM excipients list
DailyMed Link:LENACAPAVIR SODIUM at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LENACAPAVIR SODIUM
Generic Entry Dates for LENACAPAVIR SODIUM*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
SOLUTION;SUBCUTANEOUS
Generic Entry Dates for LENACAPAVIR SODIUM*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for LENACAPAVIR SODIUM

US Patents and Regulatory Information for LENACAPAVIR SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc SUNLENCA lenacapavir sodium TABLET;ORAL 215974-001 Dec 22, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Gilead Sciences Inc SUNLENCA lenacapavir sodium TABLET;ORAL 215974-001 Dec 22, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Gilead Sciences Inc SUNLENCA lenacapavir sodium SOLUTION;SUBCUTANEOUS 215973-001 Dec 22, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for LENACAPAVIR SODIUM

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3347352 C202330002 Spain ⤷  Sign Up PRODUCT NAME: LENACAPAVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR LENACAPAVIR SODICO; NATIONAL AUTHORISATION NUMBER: EU/1/22/1671; DATE OF AUTHORISATION: 20220817; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1671; DATE OF FIRST AUTHORISATION IN EEA: 20220817
3347352 22C1063 France ⤷  Sign Up PRODUCT NAME: LENACAPAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LENACAPAVIR SODIQUE; REGISTRATION NO/DATE: EU/1/22/1671 20220819
3347352 CR 2022 00052 Denmark ⤷  Sign Up PRODUCT NAME: LENACAPAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NATRIUM-LENACAPAVIR; REG. NO/DATE: EU/1/22/1671 20220819
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.